Venous stents are on the verge of being accepted as the primary treatment for patients suffering from deep venous thrombosis (DVT). Will you lead the venture developing and commercialising the stent outperforming any other venous stent?

 

The Invention

Prof. Cees Wittens of the Maastricht UMC invented a new and dedicated segmental venous stent to be used in patients with deep venous thrombosis. The segmented design uses less stent material, can be varied in length and allows for better and faster healing of the vein.

Between 23 to 60% of DVT patients suffers from post thrombotic syndrome (PTS) including serious complaints, decreasing their quality of life significantly. Although improvements in the venous stent field are being made, the currently used stents are quite stiff and made out of a lot of material, causing several complications like migration. A stent design with less material and with neither a very high or low flexibility makes that the stent grows smoothly into the vein wall, leading to multiple advantages for the patient like better healing, less anticoagulation use and increased comfort.

 

The Startup CEO

The Startup CEO will be responsible for developing and executing the overall business strategy, actively supported by NLC The Healthtech Venture Builder and partnering with Prof. Cees Wittens (who offers excellent technical expertise). Your main responsibilities will be:

  • Fundraising. Initially for pre-clinical and clinical studies and later also for product development, certification and market entry.
  • Manage (the outsourcing of) clinical trials.
  • Manage the certification process of the class III medical device.
  • Prepare and initiate the go-to-market strategy.

 

Competencies required

  • Entrepreneurial drive.
  • Developing action oriented (commercial) strategy.
  • Executing plans. Project Management with strong problem solving skills.
  • Leading individuals and teams.
  • Networking and influencing at all levels of seniority.

 

Experience required

  • Academic qualifications
  • Carried overall responsibility for a company, business or (development) program.
  • Demonstrated track record in the field of vascular surgery or DVT.
  • Experience with (or knowledge of) the certification of class III medical devices.
  • Strong presentation and negotiation skills, ideally including experience fundraising for clinical trials.

 

Other

  • The CEO is interested in equity-based remuneration and accepts tying initial cash compensation to the success of founding and funding the company.
  • Co-funding is possible

For more information please contact Eva van Rooijen via: eva.vanrooijen@nlc.health